The full audited consolidated financial statements as of and for the year ended December 31, 2024, can be found in BioNTech's Annual Report on Form 20-F filed today with the United States Securities ...

The benchmark US stock measures were trending lower before Monday's opening bell as traders await fresh inflation data later in the week. Standard & Poor's 500 declined 1.1%, the Dow Jones Industrial ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...

SVB Wealth LLC bought a new stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) in the fourth quarter, Holdings ...

Ugur Sahin, the co-founder and CEO of BioNTech SE (BNTX), sold $119.58 million worth of the Germany-based biotechnology ...

Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seventeen analysts that are covering the firm, Marketbeat Ratings reports. Three ...

In a report released yesterday, Harry Gillis from Berenberg Bank maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

Canaccord Genuity analyst William Maughan maintained a Buy rating and increased the price target from $171 to $171.44 on Nov. 27, 2024. This analyst has an accuracy rate of 71%. JP Morgan analyst ...

S&P 500 E-Mini futures (ESH25) are down -0.90%, andMarch Nasdaq 100 E-Mini futures (NQH25) are down -1.04% this morning, ...

BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with ...

In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against other best immunology stocks to buy now. Immunology is a rapidly advancing field with significant ...